[Translation]

October 23, 2026

MEDIPAL HOLDINGS CORPORATION
Representative: Kuniaki Imagawa, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Toshiyuki Ikeuchi,
Executive Officer, Head of Corporate Communications Department,
Corporate Planning Division
Tel: +81-3-3517-5171

Notice Regarding Recording of Gain on Sale of Investment Securities (Extraordinary Income)

MEDIPAL HOLDINGS CORPORATION (the "Company") hereby announces that the following gains on sale of investment securities were generated as a result of the sale and reduction of a portion of the investment securities held by the Company.

1. Period during which the gain on sale of investment securities was generated (timing of sale)
   May 2026 to October 2026

2. Reasons for sale of investment securities
   The Company reduced its strategic shareholdings in accordance with the Corporate Governance Code and the "Action to Implement Management that is Conscious of Cost of Capital and Stock Price," disclosed on May 13, 2025.

3. Details of gain on sale of investment securities
   Shares sold: Eight (8) listed securities held by the Company
   Gain on sale of investment securities: ¥15,485 million*
   *Of this amount, ¥6,061 million was recorded as gain on sale of investment securities (extraordinary income) during the consolidated accounting period for the first quarter of the fiscal year ending March 31, 2027.

4. Future outlook
   For the impact of recording the gain on sale of investment securities (extraordinary income) on the consolidated financial results for the fiscal year ending March 31, 2027, please refer to the "Notice Regarding Revision of Forecast of Full-Year Consolidated Financial Results" announced today.

# # #

The English version of this document is a translation of the Japanese original and is provided for informational purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. If there are any inconsistencies or conflicts between the English version and the Japanese original, the Japanese original shall prevail.